KEYNOTE001 Five year data from the phase Ib trial studying pembrolizumab as treatment for aNSCLC

KEYNOTE-001: Five year data from the phase Ib trial studying pembrolizumab as treatment for aNSCLC

15:55 EDT 1 Jun 2019 | ecancermedicalscience

Dr Edward B. Garon talks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about the use of immunotherapy agent pembrolizumab as treatment for advanced non-small cell lung cancer. He explains that this phase Ib study is...

More From BioPortfolio on "KEYNOTE-001: Five year data from the phase Ib trial studying pembrolizumab as treatment for aNSCLC"